UK: Funding For Second Kymriah Indication After Talks And Price Cut
Executive Summary
UK HTA body NICE says a second indication for Novartis’s groundbreaking CAR-T cell therapy Kymriah should be covered under the Cancer Drugs Fund.
You may also be interested in...
Early Engagement On Outcomes-Based Deals Helps Unlock EU Access To Kymriah
Novartis has managed to temporarily overcome payer reservations about the real-world value of Kymriah by engaging early with payers and heath technology assessment bodies and by developing tailored outcomes-based deals for key European markets. Approaching each payer with a responsible attitude has helped too.
Scottish HTA Body OKs Vyxeos & Prevymis, But Rejects Kymriah In Lymphoma
The Scottish Medicines Consortium has OKd the use of two orphan drugs, Vyxeos for AML and Prevymis for preventing CMV reactivation, but rejected Novartis’s CAR-T therapy Kymriah, for use in lymphoma.
Mixed HTA Results As Scotland Says No To Yescarta But Yes To Kymriah
The Scottish Medicines Consortium has recommended one CAR-T therapy, Novartis’ Kymriah, for use on Scotland’s National Health Service but rejected another, Gilead’s Yescarta, claiming the company has failed to prove it would be cost-effective.